Table 4.

Autoantibody Associations With Clinical Markers of Disease Activity and Severity in Morphea and its Subtypes^a

Morphea Subtype/Autoantibody	P Value
	Limited Function	BSAb	mRSS	Localized Scleroderma Skin		PGA
				Severity Index	Damage Index	Activity	Damage
Linear
ANA	NS	.005	<.001	NS	NS	NS	NS
Anti-ssDNA	.005	.01	NS	NS	NS	NS	NS
Antihistone	.006	NS	NS	NS	NS	NS	NS
Total group of patients with morphea
ANA	NS	NS	<.001	NS	NS	NS	NS
Anti-ssDNA	.03	NS	NS	NS	NS	NS	NS
Antihistone	.007	NS	NS	NS	NS	NS	NS

Abbreviations: ANA, antinuclear antibody; Anti-ssDNA, anti–single-stranded DNA; BSA, body surface area; mRSS, modified Rodnan Skin Score; NS, nonsignificant; PGA, Physician Global Assessment.

^aOnly subtypes with statistically significant associations are shown. Generalized and plaque subtypes do not have any significant associations.

^bExtensive BSA is defined as having 3 or more body sites involved. For limited functionality and extensive BSA, 2-tailed χ² tests with Yates correction were used, except when one of the expected values in the 2 × 2 table is less than 5, in which case the 2-tailed Fisher exact test was used. For mRSS, Localized Scleroderma Skin Severity Index, Localized Scleroderma Skin Damage Index, PGA of Activity, and PGA of Damage, Wilcoxon rank sum tests were used.